The consumption of artificial sweeteners has significantly increased globally, particularly as a substitute for sugar for the management of conditions such as diabetes and obesity, which are significant risk factors for cardiovascular disease. Despite their widespread use, the health impacts of artificial sweeteners remain contentious. Research has suggested that certain sweeteners may contribute to systemic inflammation, endothelial dysfunction, and disruptions in gut microbiota, potentially altering glucose metabolism and exacerbating metabolic conditions such as diabetes and obesity. However, other studies highlight potential benefits, such as weight control and improved glucose tolerance. Still, the long-term safety of artificial sweeteners, particularly with chronic consumption, remains uncertain. This literature review explores the cardiovascular risks associated with various artificial sweeteners, focusing on the 6 US Food and Drug Administration-approved nonnutritive sweeteners, aspartame, sucralose, saccharin, acesulfame K, cyclamate, and neotame, as well as nutritive sweeteners such as polyols (erythritol, xylitol, sorbitol, and maltitol). Ongoing research, including in vitro, animal, and clinical studies, aims to clarify the long-term cardiovascular and metabolic implications of artificial sweeteners and assess the safety of their widespread use across diverse populations.

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000873DOI Listing

Publication Analysis

Top Keywords

artificial sweeteners
24
sweeteners
9
cardiovascular disease
8
conditions diabetes
8
diabetes obesity
8
artificial
6
sugar-free risk-free?
4
risk-free? exploring
4
exploring artificial
4
cardiovascular
4

Similar Publications

For the effective growth of malignant tumors, including glioblastoma, the necessary factors involve endoplasmic reticulum (ER) stress, hypoxia, and the availability of nutrients, particularly glucose. The ER degradation enhancing alpha-mannosidase like protein 1 (EDEM1) is involved in ER-associated degradation (ERAD) targeting misfolded glycoproteins for degradation in an N-glycan-independent manner. EDEM1 was also identified as a new modulator of insulin synthesis and secretion.

View Article and Find Full Text PDF

Ferric carboxymaltose (FCM) is widely used to correct anemia and replenish iron stores rapidly, particularly in Western populations. However, lower doses of FCM are typically used in East Asia, with limited research on their effectiveness, especially in postpartum women. This randomized controlled trial aimed to assess the efficacy of low-dose FCM compared with oral ferrous sulfate in increasing postpartum hemoglobin (Hb) levels and replenishing iron stores in East Asian women.

View Article and Find Full Text PDF

Supporting islet function in a PVDF membrane based macroencapsulation delivery device by solvent non-solvent casting using PVP.

PLoS One

March 2025

Cell Biology-Inspired Tissue Engineering (cBITE), MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, The Netherlands.

Type 1 diabetic (T1D) patients are life-long dependent on insulin therapy to keep their blood glucose levels under control. An alternative cell-based therapy for exogenous insulin injections is clinical islet transplantation (CIT). Currently the widespread application of CIT is limited, due to risks associated with the life-long use of immunosuppressive drugs to prevent rejection of donor cells.

View Article and Find Full Text PDF

A disposable, self-powered enzymatic biofuel cell (BFC) sensor integrated with a hollow microneedle array (HMNA) for glucose monitoring in interstitial fluid (ISF) is reported. The HMNA enables painless and minimally invasive ISF extraction. The BFC uses dehydrogenase (GDH) in conjunction with NAD, diaphorase (DI), and vitamin K (VK) serving as electron transfer mediators as the anode catalyst and Prussian blue (PB) as the electrochromic cathode.

View Article and Find Full Text PDF

An adaptive, continuous substrate feeding strategy based on evolved gas to improve fed-batch ethanol fermentation.

Appl Microbiol Biotechnol

March 2025

Department of Agricultural, Food & Nutritional Science, University of Alberta, T6G 2P5, Edmonton, Canada.

Advances in the ethanol fermentation process are essential to improving the performance of bioethanol production. Fed-batch fermentation is a promising approach to increase the final ethanol titer, which benefits the recovery in the bioethanol industry's downstream process. However, the development of feeding strategies, a crucial control variable in the fed-batch approach, is limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!